Results 21 to 30 of about 75,992 (272)

Nivolumab cohort

, 2022
clinical course in AEC patients treated with ...
Naoki Takegawa (10148882)
core   +1 more source

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

Frontiers in Oncology, 2021
BackgroundNivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure.
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang   +8 more
doaj   +1 more source

Agnostic evaluation of ipilimumab and nivolumab association : a metanalysis [PDF]

, 2020
Background: Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-lasting effect.
Marchetti P., Giannarelli D., Botticelli A., Ascierto A. P., Curigliano G.   +4 more
core   +3 more sources

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

ESMO Open, 2019
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers.
Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Kazuhide Higuchi, Narikazu Boku   +12 more
doaj   +1 more source

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

, 2022
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion.
Abaskharoun, Mena, Rutkowski, Piotr, Srivastava, Shivani, Lao, Christopher D, Long, Georgina V, Gogas, Helen J, Dalle, Stéphane, Hamilton, Melissa, Castillo Gutiérrez, Erika, De Menezes, Juliana Janoski, Arance, Ana, Grob, Jean-Jacques, Lipson, Evan J, Sobiesk, Anne Marie, Li, Bin, Hodi, F Stephen, Tawbi, Hussein A, Keidel, Sarah, Nair, Suresh G., MD, Schadendorf, Dirk, Matamala, Luis, Ascierto, Paolo A, Simonsen, Katy L   +22 more
core   +1 more source

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy

Advances in Radiation Oncology, 2018
Purpose: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment.
Neha P. Amin, MD, Maliha Zainib, BS, Sean M. Parker, BS, Manuj Agarwal, MD, Malcolm D. Mattes, MD   +4 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States

Frontiers in Pharmacology, 2021
Background: In a recent randomized, phase 3 trial (CheckMate 9ER), nivolumab combined with cabozantinib significantly improved patient outcomes compared with sunitinib.
SiNi Li, SiNi Li, SiNi Li, JianHe Li, LiuBao Peng, YaMin Li, YaMin Li, XiaoMin Wan   +7 more
doaj   +1 more source

AEC with nivolumab

, 2023
clinical course in AEC patients treated with ...
Naoki Takegawa (10148882)
core   +1 more source

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations

EJC Skin Cancer
Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some.
Sophia Kreft, Tommaso Bosetti, Rebecca Lee, Paul Lorigan   +3 more
doaj   +1 more source

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer

Cancer Control, 2021
Introduction: Corticosteroids are used to treat immune-related adverse events (irAEs) associated with nivolumab. However, patients with non-small-cell lung cancer who are administered corticosteroids before the initiation of nivolumab treatment are ...
Kengo Umehara, Kaori Yama, Keisuke Goto, Azusa Wakamoto, Tae Hatsuyama, Osamu Honjo, Toyohiro Saikai, Akihisa Fujita, Hideki Sato   +8 more
doaj   +1 more source